GlassScriptPhysician profile
Dorothy J Park
NPI 1932183852
$6,476.90
in general payments reported to CMS, 2019-2025
28 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $801 · 2020: $277 · 2021: $492 · 2022: $1,129 · 2023: $995 · 2024: $1,498 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,778.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,158.99 | 2022-2025 | Infuse, Xiidra, Miebo |
| Alcon Vision LLC | $934.68 | 2019-2025 | Total30, Tryptyr, Rocklatan |
| Abbvie INC. | $641.18 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $374.00 | 2022-2024 | Cequa |
| Oyster Point Pharma, INC. | $285.14 | 2022-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $260.07 | 2019-2021 | |
| Horizon Therapeutics Plc | $249.79 | 2022-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $248.94 | 2020-2021 | |
| Coopervision INC. | $222.63 | 2023-2024 | Myday Contact Lens, Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $218.49 | 2019-2023 | Acuvue |
| Allergan, INC. | $218.18 | 2019-2022 | |
| Sight Sciences, INC. | $209.56 | 2023-2024 | Omni Surgical System |
| Tarsus Pharmaceuticals, INC. | $186.15 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $165.77 | 2022 | |
| Biotissue Holdings INC. | $163.35 | 2019-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $124.02 | 2021 | |
| Novartis Pharmaceuticals Corporation | $121.83 | 2019 | |
| Mallinckrodt Hospital Products INC. | $111.74 | 2025 | Acthar |
| New World Medical,INC. | $105.40 | 2025 | Via360, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Optos, INC. | $101.97 | 2019 | |
| Alcon Research LLC | $85.38 | 2019 | |
| Rxsight INC | $78.95 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Astellas Pharma US INC | $73.41 | 2024 | Izervay |
| Dompe US, INC. | $57.28 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $29.90 | 2021 | |
| Thea Pharma INC. | $25.27 | 2023 | Iyuzeh |
| Maculogix, INC. | $17.41 | 2019 | |
| Abb Con-Cise Optical Group LLC | $7.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorothy Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.